Seamless Oncology-Drug Development
The DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Interview with Dr. Alice Shaw on a new model for accelerating the development of promising oncology drugs. (10:06)Download Increasingly, firms developing cancer drugs are forgoing standard phased development for a seamless approach of adding cohorts to a first-in-human trial to study doses and activity in various cancers. Key regulatory interactions and protections may therefore be missing.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The traditional stepwise drug development paradigm that classifies studies in phases is slowly changing to an approach related to specific objectives [13].”
Citations
The citation lists are queued
They are fetched later and appear here then.
Cited by 126
Metadata
- Authors
- Prowell, T. M., Theoret, M. R., & Pazdur, R.
- Affiliations
- United States Food and Drug Administration (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-05-26
- Volume
- 374
- Issue
- 21
- Pages
- 2001-2003
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2339302618
- Cited by
- 126
- References
- 0
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 6 · 2023: 17 · 2022: 6 · 2021: 14 · 2020: 6 · 2019: 14 · 2018: 27 · 2017: 23 · 2016: 9
- FWCI
- 24.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Keywords
- anticancer drug development, accelerated drug development, regulatory interactions, anticancer agents, dose escalation
- MeSH terms
- Antineoplastic Agents, Clinical Trials as Topic, Humans, Neoplasms, United States, United States Food and Drug Administration, Drug Approval, Therapeutic Human Experimentation, Drug Discovery, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Seamless Oncology-Drug Development. https://app.cochat.ai/papers/10.1056/nejmp1603747
- The paper
- Prowell, T. M., Theoret, M. R., & Pazdur, R. (2016). Seamless Oncology-Drug Development. New England Journal of Medicine. https://doi.org/10.1056/nejmp1603747
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.